The discovery of artemisinin (ART) 1 and its semisynthetic derivatives dihydroartemisinin (DHA), artemether (AM) and artesunate (AS) (Fig. 1 ) triggered 2 the search for superior semisynthetic artemisinins 3 and synthetic peroxide antimalarials. 4 The first attempts to improve synthetic peroxide 5 and semisynthetic artemisinin 6 antimalarial specificity and biopharmaceutical properties by incorporating weak base functional groups and heterocycles were largely unsuccessful. Since that time, however, continued work [7] [8] [9] [10] [11] [12] in this area has produced some encouraging results as illustrated by synthetic peroxides 1 (OZ209) 13 and 2 (trioxaquine), 14 and semisynthetic artemisinin 3 (artemisone) 15 ( Fig. 2) . In this paper, we describe the synthesis 16 and antimalarial properties of thirty 1,2,4-dispiro trioxolanes (secondary ozonides) containing azole heterocycles and aliphatic and aromatic amine functional groups. Metabolism and pharmacokinetic data are presented for selected trioxolanes. Our aim was to identify a potent weak base analog of 1 with high oral activity, good biopharmaceutical properties, and low toxicity.
Trioxolanes 13, 14, 15, and 17 were obtained by postozonolysis transformations of their precursor trioxolane esters and phthalimides; the latter were obtained by Griesbaum coozonolysis 17, 18 reactions between the O-methyl oximes of 2-adamantanone (4) or 4-tert-butyl cyclohexanone (5) (for 13) and the appropriate 4-substituted cyclohexanones 6 (Scheme 1). Symmetrical oxime ethers such as 4 preclude the syn-anti isomerism of the resulting carbonyl oxide intermediates, and ensure that the stereochemistry of the cycloaddition is only a function of the starting material ketones. For 4-substituted cyclohexanones, the major trioxolane isomers are uniformly cis with the substituent and peroxo groups at the equatorial and axial positions, respectively. 19, 20 With the exception of 31, each of the trioxolanes reported herein is single cis isomer. Indeed, X-ray crystallographic analysis 21 of 7, 19 the phthalimide precursor of 14, reveals that it has a cis configuration (Fig. 3 ).
Alcohol 17 (96%) was obtained by lithium borohydride/ lithium triethylborohydride 22 reduction of its precursor methyl ester (cis). Conversion of 17 to its mesylate, followed by azide formation and triphenyl phosphine reductions afforded amine 15 (52% overall). Azole 45 (61%) was formed by treatment of the mesylate derivative of 17 with imidazole/NaH. Amines 13 (65%) and 14 (69%) were obtained by hydrazinolysis of their precursor phthalimides. Unlike amine 15, amines 1 and 14 were unstable as hydrochloride salts, but were quite stable as mesylate or tosylate salts.
Alkylation of 1 with 2-bromoacetamide and 2-chloropyrimidine in the presence of K 2 CO 3 afforded 28 (44%) and 36 (20%) (Scheme 2). Carbamate 19 (63%) and guanidine 20 (56%) were obtained by treatment of 1 with ethyl chloroformate/Et 3 N and 1H-pyrazole-1-carboxamidine hydrochloride/Et 3 N. Amine 27 (55%) was obtained by reductive amination of formaldehyde with amine 1. Aminoxy trioxolane 18 (69% overall) was obtained by Mitsunobu reaction of alcohol 8 with N-hydroxyphthalimide followed by hydrazine deprotection. Reductive amination reactions were used to obtain amines 32 (74%) and 31 (45%) (1:1 mixture of cis and trans achiral diastereomers) from ketone 9 and amines 22 (36%), 23 (39%),25 (46%), 30 (61%), and 34 (49%) from aldehyde 10 (Scheme 2). Imidazole 41 (70%) was obtained from 10 by treatment with 40% aq glyoxal followed by 7 N methanolic ammonia. Reaction of mesylate 11 with the anions of pyrazole and methyl 4-imidazole carboxylate afforded 39 (81%) and the isomeric imidazole ester precursors of 43 (20%) and 44 (47%). Successive treatment of these esters with 15% KOH, BOC anhydride, and 7 N methanolic ammonia afforded imidazole amides 43 (11% overall) and 44 (27% overall). Tetrazole 42 (69% overall) was obtained by successive treatment of active ester 12 with 3-aminopropionitrile, trimethylsilyl azide/TPP/DIAD, sodium bicarbonate, and 1 M HCl according to the method of Johansson et al. 23 Trioxolanes 1, 7-12, 16, 21, 24, 26, 29, 33, 35, 37, 38, and 40 were obtained as previously described. In vitro and in vivo antimalarial activities 13 were measured using the chloroquine-resistant K1 and chloroquine-sensitive NF54 strains of Plasmodium falciparum, and Plasmodium berghei-infected mice, respectively. In vivo data were determined using single 10 mg/kg oral doses of the trioxolanes administered on day 1 post-infection in a non-solubilizing, standard suspension vehicle (SSV) formulation comprising 0.5% w/v carboxymethyl cellulose, 0.5% v/v benzyl alcohol, 0.4% v/v Tween 80, and 0.9% w/v sodium chloride in water. The complete lack of activity for 13 demonstrates the essential contribution of the spiroadamantane ring system to the antimalarial properties of 1 and its analogs. For the homologous series of primary amines 14, 1, and 15, in vitro potencies and metabolic stabilities were essentially invariant, but in vivo activity was the highest for 1 ( Table 1 ). The primary alcohol isosteres 16, 8, and 17 were similarly potent in vitro, but were not as effective in vivo. The weaker in vivo activities of the alcohols may be due in part to their decreased metabolic stabilities (predicted hepatic ER > 0:5), presumably a function of their greater lipophilicities. The poor antimalarial profile of 18, the aminoxy isostere of 15, shows that a basic amino group is required for optimal antimalarial activity. On the other hand, the data for 20 show that substituting a more basic guanidine for the primary amine in 1 diminishes antimalarial potency by an order of magnitude. Ethyl carbamate 19, a potential prodrug of 1, had an antimalarial profile equal to that of 1, but was considerably less metabolically stable due, presumably, to hydrolysis of the carbamate functional group.
The data for secondary and tertiary aliphatic amines are depicted in Table 2 . With the exception of amino acid 23, all of the secondary amines were quite potent (IC 50s <1 ng/mL). Of these, only cyclopropyl amine 21 and diamine 26 had activities <99.5%
The data for secondary aromatic amines are depicted in Table 3 . All of these had good potencies in vitro (IC 50s <5 ng/mL), and with the exception of 36, had in vivo activities P 99.5%. Anilides and sulfanilamides 31-34 were considerably more lipophilic (Log D pH 7.4 >5) than their aliphatic amine counterparts shown in Table 2 . Not surprisingly, 31 and 32 were rapidly metabolized as was 34 (predicted ER > 0:7). Interestingly, pyridine 13, 20 Log D pH 7.4 denotes the octanol/buffer partition coefficient at pH 7.4 which is relevant for the ionizable analogs. b Mean from (n = 2-3). Individual measurements differed by less than 50%. c Groups of three P. berghei-infected MORO mice were treated orally one day post-infection with trioxolanes dissolved or suspended in SSV.
Antimalarial activity was measured by percent reduction in parasitemia on day three post-infection. Individual measurements differed by less than 10%. d Predicted hepatic extraction ratios (ER) using human liver microsomes. 35 and pyrimidine 36 were similarly potent in vitro, but the less basic 36 was much less active than 35 in vivo.
The data for the azoles are depicted in Table 4 . With the exception of acidic tetrazole 42, all had IC 50s < 2 ng/mL. Compared to imidazole 38, the less basic pyrazole (39) and triazole (40) isosteres were equally potent in vitro, but only 40 was as active in vivo, and it was unexpectedly less stable metabolically. Compared to N-alkyl imidizole 38, the more polar 2-substituted imidazole 41 was more potent in vitro, but, it was much less active in vivo. Imidazoles 43 and 44 show that increasing the polarity of 38 by carboxamide substitution maintains antimalarial efficacy, but where measured (44), decreases metabolic stability. Imidazole 45 shows that extending the link between the cyclohexane and imidazole heterocycle increases lipophilicity but does not enhance antimalarial efficacy.
To assess whether some of the new weak base trioxolanes could cure P. berghei-infected mice, we administered a 3 · 10 mg/kg divided dose on days +1, +2, and +3 post-infection. In this experiment, 1 was completely curative, semisynthetic artemisinins AM and AS provided no cures, 13 and 24, 31, 32, and 38 cured 1/5, 2/5, 4/5, and 0/5 of the infected mice, respectively. Selected trioxolanes were administered intravenously (IV) and orally (PO) to rats 24 and pharmacokinetic data for 1, 8, 24, 38, DHA, and AM are shown in Table 5 . The data indicated that alcohol 8 was rapidly cleared after IV dosing by conversion to its less active 25 carboxylic acid metabolite. After PO dosing, plasma concentrations of 8 were not detected indicating very low oral bioavailability. Weak base trioxolanes 1, 24, and 38 each had a considerably longer half-life compared to 8 and oral bioavailabilities ranging from 30% to 60%.
Preliminary toxicological investigations (5-day toxicity studies in male rats with daily oral administration) indicated toxicological profiles of 1, 24, and 38 similar to that of artesunate, including gastric irritation, hepatocellular In summary, compared to primary amino trioxolanes 14, 1, and 15, alcohol (16, 8, 17) and aminoxy (18) isosteres, and guanidine (20) and amino acid (23) analogs had inferior antimalarial and biopharmaceutial profiles. As exemplified by imidazole 38, the good antimalarial profiles of several weak base azoles show that trioxolanes do not require an aliphatic amino functional group for high antimalarial activity. The reduced potency of 23 and 42 is consistent with our previous observation 25 that trioxolane carboxylic acids have weak antimalarial activities. Although none of these new weak base trioxolanes had antimalarial profiles superior to that of 1, amino amides 24, 25, 29, and 31-34 were nearly as effective; however each of these was less stable metabolically than 1. Indeed, lipophilic trioxolanes tended to be less stable metabolically than their more polar counterparts. Importantly, 1, 24, and 38 each displayed an improved half-life and oral bioavailability relative to DHA and AM, and the latter (24, 38) were less toxic than 1. Future studies will determine the potential of weak base trioxolanes as antimalarial drug development candidates. Table 4 . Lipophilicity, metabolic stability, and activity of azole trioxolanes against P. falciparum in vitro and P. berghei in vivo 
